Less than a tenth of people that would benefit from obesity jabs including Wegovy have access to them, caution the World Health Organization as it publishes its inaugural guidance on the drugs.
Given more than one billion people worldwide now classified as obese, it is advocating for broader and more equitable availability to these injectable treatments.
According to estimates, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The new guidance recognises that obesity is a long-term condition that can be addressed with holistic and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are significant obstacles to universal access to the jabs that can assist patients in reducing substantial body mass, notes the agency.
Skinny Jab Shortage
Even in the present most optimistic outlook, the manufacturing of such drugs might only reach approximately 100 million people – fewer than 10% of the global need, as stated by the WHO.
The advice urges governments and firms to expand access, via strategies including licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Drugs Work
The injections mimick a biological compound to slow digestion, suppress the appetite and enhance satiety so individuals reduce food intake.
Patients typically begin shedding pounds in the initial weeks of commencing the regular doses.
Evidence suggests patients may regain a significant portion a year later of discontinuing the drug, when their typical appetite come back.
To be above a healthy weight elevates your likelihood for experiencing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts people in all nations and was linked to over three and a half million fatalities worldwide in 2024, according to the health agency.
